DOI QR코드

DOI QR Code

Effect of First Line Gastric Cancer Chemotherapy Regime on the AGS Cell Line - MTT Assay Results

  • Alizadeh-Navaei, Reza (Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences) ;
  • Rafiei, Alireza (Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences) ;
  • Abedian-Kenari, Saeid (Immunogenetic Research Center, Mazandaran University of Medical Sciences) ;
  • Asgarian-Omran, Hossein (Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences) ;
  • Valadan, Reza (Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences) ;
  • Hedayatizadeh-Omran, Akbar (Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences)
  • Published : 2016.02.05

Abstract

Background: Combination chemotherapy regimes are common treatments for cancer. The aim of this study was to evaluation the effect of individual chemotherapeutic agents in comparison with a first line chemotherapy regime treatment in the AGS gastric cancer cell line by MTT assay. Materials and Methods: In this experimental study, AGS cells were grown in RPMI-1640 supplemented with 10% fetal calf serum and 100 IU/ml penicillin, and $10{\mu}g/ml$ streptomycinin, under a humidified condition at $37^{\circ}C$ with 5% CO2. All cells were washed with PBS and detached with trypsin, centrifuged and 8000 cells re-plated on to 96- well plates. LD50 doses of Epirubicin, Cisplatin and 5-fluorouracil were added to each well in mono or triple therapy. Anti-proliferative activities were determined by MTT assay after 24, 48 or 72 h. Results: Results of MTT assays showed that there were no significant differences among 3 drugs in monotherapy (p=0.088), but there was significant difference between combination therapy with epirubicin (P=0.031) and 5FU (p=0.013) on cell survival at 24 h. After 48 and 72 hours, cell viability showed significant differences between the 3 drugs (p=0.048 and P=0.000 for 48 and 72 h, respectively) and there was significant difference between combination therapy with epirubicin (P=0.035 and P=0.002 for 48 and 72 h, respectively). Conclusions: The results showed no significant differences between these chemotherapy drugs each given alone, but combination therapy with 3 drugs had significant effects on cell viability in comparison with epirubicin alone.

Keywords

Gastric cancer;chemotherapy;AGS cell line;MTT;monotherapy;combined therapy

Acknowledgement

Supported by : Mazandaran University of Medical Sciences

References

  1. Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3205-9. https://doi.org/10.1200/JCO.2006.10.4968
  2. Armstrong B, Doll R (1975). Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer, 15, 617-31. https://doi.org/10.1002/ijc.2910150411
  3. Arnold M, Moore SP, Hassler S, et al (2014). The burden of stomach cancer in indigenous populations: a systematic review and global assessment. Gut, 63, 64-71. https://doi.org/10.1136/gutjnl-2013-305033
  4. Benson AB (2008). Advanced gastric cancer: an update and future directions. Gastrointest Cancer Res, 2, 47-53.
  5. Brenner H, Rothenbacher D, Arndt V (2009). Epidemiology of stomach cancer. Methods Mol Biol, 472, 467-77. https://doi.org/10.1007/978-1-60327-492-0_23
  6. Choi YY, Noh SH, Cheong JH (2015). Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J, 56, 1177-85. https://doi.org/10.3349/ymj.2015.56.5.1177
  7. Guedes MT, de Jesus JP, de Souza Filho O, et al (2014). Clinical and epidemiological profile of cases of deaths from stomach cancer in the National Cancer Institute, Brazil. Ecancermedicalscience, 8, 445.
  8. Kim YH (2005). Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat, 37, 79-86. https://doi.org/10.4143/crt.2005.37.2.79
  9. Lin X, Zhao Y, Song WM, et al (2015). Molecular classification and prediction in gastric cancer. Comput Struct Biotechnol J, 13, 448-58. https://doi.org/10.1016/j.csbj.2015.08.001
  10. Lordick F, Siewert JR (2006). [Perioperative chemotherapy vs. surgery alone in resectable gastroesophageal carcinomas. Results of the MAGIC study]. Chirurg, 77, 1166-7. https://doi.org/10.1007/s00104-006-1249-5
  11. Park JK, Lee SH, Kang JH, et al (2004). Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs, 15, 809-18. https://doi.org/10.1097/00001813-200409000-00011
  12. Pinedo HM, Peters GF (1988). Fluorouracil: biochemistry and pharmacology. J Clin Oncol, 6, 1653-64. https://doi.org/10.1200/JCO.1988.6.10.1653
  13. Suttie SA, Park KG, Smith TA (2007). [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. Br J Cancer, 97, 902-9. https://doi.org/10.1038/sj.bjc.6603971
  14. Tsugane S, Sasazuki S, Kobayashi M, et al (2004). Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. Br J Cancer, 90, 128-34. https://doi.org/10.1038/sj.bjc.6601511
  15. Weinreich J, Archid R, Bajaeifer K, et al (2015). Growth and Chemosensitivity of Gastric Adenocarcinoma and Non-Malignant Cell Lines in Response to Novel Anti-Cancer Drug Combinations. Chemotherapy, 60, 346-52. https://doi.org/10.1159/000438943
  16. Yamane N, Makino M, Kaibara N (1999). S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells. Cancer, 85, 309-17. https://doi.org/10.1002/(SICI)1097-0142(19990115)85:2<309::AID-CNCR7>3.0.CO;2-X
  17. Zoli W, Ricotti L, Tesei A, et al (2004). Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res, 10, 1500-7. https://doi.org/10.1158/1078-0432.CCR-1107-03

Cited by

  1. Combination treatment of all-trans retinoic acid (ATRA) and γ-secretase inhibitor (DAPT) cause growth inhibition and apoptosis induction in the human gastric cancer cell line vol.70, pp.2, 2018, https://doi.org/10.1007/s10616-018-0199-3